Biodexa Pharmaceuticals Launches New Corporate and Clinical Trials Websites
New Corporate Website
Our new website reflects the company’s evolution from a drug delivery technology organisation to a drug development company focused on rare / orphan diseases and oncology with a mission to advance the development of medicines that offer patients a better future.
Clinical Trials Site
A critical component of the drug development process is the evaluation of the safety and efficacy of our investigational medicines in clinical trials. We rely on, and appreciate the role of, volunteers who enroll in our clinical programmes, because they help us better understand the potential benefits and risks of our investigational therapies.
Our newly launched reSOLVEtrials website aims to inform patients who might be considering enrolling in a clinical trial allowing them to better assess what may be involved and their suitability for such study as well as providing details on the location of studies and their principal investigators. This will enable patients to contact the sites directly or discuss this information with their treating physicians .
For more information, please contact:
Tel: +44 29 20480 180 |
www.biodexapharma.com |
About Biodexa Pharmaceuticals PLC MTX110 is a liquid formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity. Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa’s headquarters and R&D facility is in |
Forward-Looking Statements
Certain statements in this announcement may constitute "forward-looking statements" within the meaning of legislation in the
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the
Source:
2023 GlobeNewswire, Inc., source